Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

McDermott, Martina S J; Browne, Brigid C; Conlon, Neil T; O'Brien, Neil A; Slamon, Dennis J; Henry, Michael; Meleady, Paula; Clynes, Martin; Dowling, Paul; Crown, John; O'Donovan, Norma

McDermott, Martina S J; Browne, Brigid C; Conlon, Neil T; O'Brien, Neil A; Slamon, Dennis J; Henry, Michael; Meleady, Paula; Clynes, Martin; Dowling, Paul; Crown, John; O'Donovan, Norma.

Afiliação

McDermott MSJ; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Browne BC; Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research Sydney, Sydney, NSW, Australia.
Conlon NT; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
O'Brien NA; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Slamon DJ; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Henry M; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Meleady P; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Clynes M; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Dowling P; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.
Crown J; Department of Biology, National University of Ireland, Maynooth, Maynooth, Co, Kildare, Ireland.
O'Donovan N; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

Mol Cancer ; 22(1): 175, 2023 Oct 30.

Article em En | MEDLINE | ID: mdl-37915024

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: Mol Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Irlanda

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google